Phase II trial of topically applied miltefosine solution in patients with skin-metastasized breast cancer

British Journal of Cancer

Volumn 79, Issue 7-8, 1999, Pages 1158-1161

  Terwogt, J M Meerum ^a,b   Mandjes, I A M ^a   Sindermann, H ^c   Beijnen, J H ^a,b   Ten Bokkel Huinink, W W ^a  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b SLOTERVAART HOSPITAL   (Netherlands)

^c ASTA MEDICA AG   (Germany)

Author keywords

Breast cancer; Miltefosine; Skin metastases; Topical administration

Indexed keywords

DRUG VEHICLE; GLYCEROL ETHER; MILTEFOSINE; PARAFFIN;

ADULT; AGED; ARTICLE; BREAST CANCER; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG PENETRATION; FEMALE; HUMAN; NAUSEA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SKIN MANIFESTATION; SKIN METASTASIS; TOPICAL DRUG ADMINISTRATION;

ADMINISTRATION, TOPICAL; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MIDDLE AGED; PHOSPHORYLCHOLINE; SKIN NEOPLASMS; VEHICLES;

EID: 0033048898     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6690184     Document Type: Article

References (23)

1. Ando K, Kodama K, Kato A, Tamura G and Arima K (1972) Antitumor activity of glycerylethers. Cancer Res 32: 125-129
2. Berkovic D, Grunwald U, Menzel W, Unger C, Hiddeman W and Fleer EA (1995) Effects of hexadecylphosphocholine on membrane phospholipid metabolism in human tumour cells. Eur J Cancer 31A: 2080-2085
3. Clive S and Leonard RCF (1997) Miltefosine in recurrent cutaneous breast cancer. Lancet 349: 621-622
4. Detmar M, Geilen CC, Wieder T, Orfanos CE and Reuter W (1994) Phospholipid analogue hexadecylphosphocholine inhibits proliferation and phosphatidylcholine biosynthesis of human epidermal keratinocytes in vitro. J Inv Derm 102: 490-494
5. Dummer R, Krasovec M, Roeger J, Sindermann H and Burg G (1993) Topical administration of hexadecylphosphocholine in patients with cutaneous lymphomas: results of a phase I/II study. J Am Academy Derm 29: 963-970
6. Eibl H and Unger C (1990) Hexadecylphosphocholine, a new and selective antitumor drug. Cancer Treatment Rev 17: 233-242
7. Eibl H, Unger C, Fleer EAM, Kim DJ, Berger MR and Nagel GA (1986) Hexadecylphosphocholine, a new antineoplastic agent: cytotoxic properties in leukaemic cells. J Cancer Res Clin Oncol 111: S24
8. Fichtner I, Zeisig R, Naundorf H, Jungmann S, Arndt D, Asongwe G, Double JA and Bibby MC (1994) Antineoplastic activity of alkylphosphocholines (APC) in human breast carcinomas in vivo and in vitro; use of liposomes. Breast Cancer Res Treatment 32: 269-279
9. Goppelt-Struebe M and Winter I (1995) Effects of hexadecylphosphocholine on fatty acid metabolism: relation to cytotoxicity. Cancer Chemother Pharmacol 35: 519-526
10. Hilgard P, Stekar J, Voegeli R, Engel J, Schumacher W, Eibl H, Unger C and Berger MR (1988) Characterization of the anti-tumor activity of hexadecylphosphocholine. Eur J Cancer Clin Oncol 24: 1457-1461
11. Hilgard P, Harleman JH, Voegeli R, Maurer HR, Echarti C and Unger C (1989) The antineoplastic activity of hexadecylphosphocholines. Proc Am Ass Cancer Res 30: 2310
12. Hilgard P, Klenner T, Stekar J and Unger C (1993) Alkylphosphocholines: a new class of membrane-active anticancer agents. Cancer Chemother Pharm 32: 90-95
13. Planting AST, Stoter G and Verweij J (1993) Phase II study of daily oral miltefosine (hexadecylphosphocholine) in advanced colorectal cancer. Eur J Cancer 29A: 518-519
14. Unger C and Eibl H (1991) Hexadecylphosphocholine: preclinical and first clinical results of a new antitumor drug. Lipids 26: 1412-1417
15. Unger C, Eibl H, von Heyden HW and Nagel GA (1984) Reversible opening of the blood-brain-barrier for drugs transfer by short-chain alkyl glycerols. Proc Am Soc Clin Oncol 20: 25
16. Unger C, von Heyden HW, Breiser A, Nagel CA and Eibl H (1988) Etherlipids in the topical treatment of skin metastases. J Cancer Res Clin Oncol 114: S40
17. Unger C, Damenz W, Fleer EAM, Kim DJ, Breiser A, Hilgard P, Engel J, Nagel G and Eibl H (1989) Hexadecylphosphocholine, a new ether lipid analogue. Acta Oncologica 28: 213-217
18. Unger C, Peukert M, Sindermann H, Hilgard P, Nagel G and Eibl H (1990) Hexadecylphosphocholine in the topical treatment of skin metastases in breast cancer patients. Cancer Treatment Rev 17: 243-246
19. Unger C, Sindermann H, Peukert M, Hilgard P, Engel J and Eibl H (1992) Hexadecylphosphocholine in the topical treatment of skin metastases in breast cancer patients. Progr Exp Tumor Res 34: 153-159
20. Verweij J, Planting A, van der Burg M and Stoter G (1992) A dose-finding study of miltefosine (hexadecylphosphocholine) in patients with metastatic solid tumours. J Cancer Res Clin Oncol 118: 606-608
21. Verweij J, Krzemieniecki K, Kok T, Poveda A, van Pottelsberghe C, van Glabbeke M and Mouridsen H (1993) Phase II study of miltefosine in advanced soft tissue sarcomas of the adult - an EORTC soft tissue and bone sarcoma group study. Eur J Cancer 29A: 208-209
22. Verweij J, Gandia D, Planting AST, Stoter G and Armand JP (1993) Phase II study of oral miltefosine in patients with squamous cell head and neck cancer. Eur J Cancer 29A: 778-779
23. WHO (1997) WHO Handbook for Reporting Results of Cancer Treatment. World Health Organization: Geneva